Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in the UK / NCT05967091
Active, not recruiting Not applicable

Ryme Medical TLD Pilot Study

NCT05967091 · tracked via the Priya Life Science UK tracker
Sponsor
Ryme Medical, Inc
Phase
Not applicable
Started
2024-03-06
Last updated
2025-08-13

Condition(s) studied

Chronic Obstructive Pulmonary Disease

Investigational drug(s) / intervention(s)

Targeted Lung Denervation

Targeted Lung Denervation: Targeted Lung Denervation (TLD) is a bronchoscopically guided, minimally invasive procedure using the Ryme Medical Lung Denervation System

Study summary

Targeted lung denervation (TLD) with the Ryme Medical Lung Denervation System in patients with chronic obstructive pulmonary disease (COPD) - Ryme Medical TLD Pilot Study

Eligibility

Sex
ALL
Min age
40 Years
Max age
—
Healthy volunteers
No
Key Inclusion Criteria: * Symptomatic chronic obstructive pulmonary disease * ≥40 years of age * Smoking history of at least 10 pack years * Candidate for bronchoscopy in the opinion of the Investigator Key Exclusion Criteria: * Recent COPD exacerbation or respiratory infection * Prior lung intervention with device in place * Pulmonary nodule or malignancy requiring treatment * Current chemotherapy or radiation therapy and/or has received treatment within 6 months * Current smoker, using e-cigarettes or vaping, or taking any inhaled substances not prescribed by a physician * Clinically significant serious or unstable medical conditions (e.g., heart disease requiring treatment, uncontrolled diabetes) * Pregnant, nursing, or intent to become pregnant during study duration

Primary outcome measure(s)

  • Device Safety — 30 Days
    Serious adverse events associated with the Ryme Medical Lung Denervation System

Trial sites (7)

FacilityCityRegionStatus
Melbourne Health - The Royal Melbourne Hospital Melbourne Australia
Macquarie University Sydney Australia
Karl Landsteiner Institute for Lung Research Vienna Austria
Rigshospitalet Copenhagen Denmark
Healthycore Tbilisi Georgia
University of Groningen Medical Center Groningen Netherlands
Royal Brompton London United Kingdom

Other trials for the same condition

A Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation Recruiting
A Study to Evaluate the Long-term Safety and Efficacy of Lunsekimig in Adult Participants With Chronic Obstructive Pulmonary Disease (COPD) Enrolling by invitation
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype Recruiting
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) Active, not recruiting
Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05967091 on ClinicalTrials.gov ↗ ← All trials in the UK